Inhibition of formyl peptide receptor in high-grade astrocytoma by CHemotaxis Inhibitory Protein of S. aureus

British Journal of Cancer

Volumn 108, Issue 3, 2013, Pages 587-596

  Boer, J C ^a   Domanska, U M ^a   Timmer Bosscha, H ^a   Boer, I G J ^b   De Haas, C J C ^b   Joseph, J V ^a   Kruyt, F A E ^a   De Vries, E G E ^a   Den Dunnen, W F A ^a   Van Strijp, J A G ^b   Walenkamp, A M E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID DERIVATIVE; ANTINEOPLASTIC AGENT; CALCIUM; CHEMOTAXIS INHIBITOR; CHEMOTAXIS INHIBITORY PROTEIN OF STAPHYLOCOCCUS AUREUS; FORMYLMETHIONYLLEUCYLLYSYLISOLEUCYLVALINE; FORMYLMETHIONYLMETHIONYLTYROSYLALANYLLEUCYLPHENYLALANINE; FORMYLPEPTIDE RECEPTOR; FORMYLPEPTIDE RECEPTOR LIKE 1; LIGAND; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTROCYTOMA; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CANCER GRADING; CELL MIGRATION; CHEMOTAXIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL RATE; TUMOR CELL; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; ASTROCYTOMA; BACTERIAL PROTEINS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CALCIUM; CELL MOVEMENT; CHEMOTAXIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM GRADING; PEPTIDE FRAGMENTS; RECEPTORS, FORMYL PEPTIDE; TUMOR CELLS, CULTURED;

EID: 84875209228     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.603     Document Type: Article

References (30)

1. de Haas CJ, Veldkamp KE, Peschel A, Weerkamp F, Van Wamel WJ, Heezius EC, Poppelier MJ, Van Kessel KP, van Strijp JA (2004) Chemotaxis inhibitory protein of Staphylococcus aureus, a bacterial antiinflammatory agent. J Exp Med 199: 687-695.
2. de Vries EG, Meijer C, Timmer-Bosscha H, Berendsen HH, de Leij L, Scheper RJ, Mulder NH (1989) Resistance mechanisms in three human small cell lung cancer cell lines establishedfrom one patient during clinical follow-up. Cancer Res 49: 4175-4178.
3. Du R, Lu KV, Petritsch C, Liu P, Ganss R, Passegue E, Song H, Vandenberg S, Johnson RS, Werb Z, Bergers G (2008) HIF1a induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 13: 206-220.
4. Durstin M, Gao JL, Tiffany HL, McDermott D, Murphy PM (1994) Differential expression of members of the N-formylpeptide receptor gene cluster in human phagocytes. Biochem Biophys Res Commun 201: 174-179.
5. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27: 4733-4740.
6. Haas PJ, de Haas CJ, Kleibeuker W, Poppelier MJ, van Kessel KP, Kruijtzer JA, Liskamp RM, van Strijp JA (2004a) N-terminal residues of the chemotaxis inhibitory protein of Staphylococcus aureus are essential for blocking formylated peptide receptor but not C5a receptor. J Immunol 173: 5704-5711.
7. Haas PJ, de Haas CJ, Kleibeuker W, Poppelier MJ, van Kessel KP, Kruijtzer JA, Liskamp RM, van Strijp JA (2004b) N-terminal residues of the chemotaxis inhibitory protein of Staphylococcus aureus are essential for blocking formylated peptide receptor but not C5a receptor. J Immunol 173: 5704-5711.
8. Huang J, Chen K, Chen J, Gong W, Dunlop NM, Howard OM, Gao Y, Bian XW, Wang JM (2010) The G-protein-coupled formylpeptide receptor FPR confers a more invasive phenotype on human glioblastoma cells. Br J Cancer 102: 1052-1060.
9. Huang J, Hu J, Bian X, Chen K, Gong W, Dunlop NM, Howard OM, Wang JM (2007) Transactivation of the epidermal growth factor receptor by formylpeptide receptor exacerbates the malignant behavior of human glioblastoma cells. Cancer Res 67: 5906-5913.
10. Kuijlen JM, Mooij JJ, Platteel I, Hoving EW, van der Graaf WT, Span MM, Hollema H, den Dunnen WF (2006) TRAIL-receptor expression is an independent prognostic factor for survival in patients with a primary glioblastoma multiforme. J Neurooncol 78: 161-171.
11. Kunkel P, Ulbricht U, Bohlen P, Brockmann MA, Fillbrandt R, Stavrou D, Westphal M, Lamszus K (2001) Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 61: 6624-6628.
12. Liao D, Corle C, Seagroves TN, Johnson RS (2007) Hypoxia-inducible factor-1a is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res 67: 563-572.
13. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 547.
14. Macheda ML, Rogers S, Best JD (2005) Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 202: 654-662.
15. Miller CR, Perry A (2007) Glioblastoma. Arch Pathol Lab Med 131: 397-406.
16. Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen PY (2008) Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70: 779-787.
17. Postma B, Poppelier MJ, van Galen JC, Prossnitz ER, van Strijp JA, de Haas CJ, van Kessel KP (2004) Chemotaxis inhibitory protein of Staphylococcus aureus binds specifically to the C5a and formylated peptide receptor. J Immunol 183: 6569-6578.
18. Rabiet MJ, Huet E, Boulay F (2005) Human mitochondria-derived N-formylated peptides are novel agonists equally active on FPR and FPRL1, while Listeria monocytogenes-derived peptides preferentially activate FPR. Eur J Immunol 35: 2486-2495.
19. Rubenstein JL, Kim J, Ozawa T, Zhang M, Westphal M, Deen DF, Shuman MA (2000) Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2: 306-314.
20. Schiffmann E, Corcoran BA, Wahl SM (1975) N-formylmethionyl peptides as chemoattractants for leucocytes. Proc Natl Acad Sci USA 72: 1059-1062.
21. Sie M, de Bont ES, Scherpen FJ, Hoving EW, den Dunnen WF (2010) Tumour vasculature and angiogenic profile of paediatric pilocytic astrocytoma; is it much different from glioblastoma? Neuropathol Appl Neurobiol 36: 636-647.
22. Sie M, Wagemakers M, Molema G, Mooij JJ, de Bont ES, den Dunnen WF (2009) The angiopoietin 1/angiopoietin 2 balance as a prognostic marker in primary glioblastoma multiforme. J Neurosurg 110: 147-155.
23. Suchorska B, Ruge M, Treuer H, Sturm V, Voges J (2011) Stereotactic brachytherapy of low-grade cerebral glioma after tumor resection. Neuro Oncol 13: 1133-1142.
24. Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501.
25. Vredenburgh JJ, Desjardins A, Herndon 2nd JE, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25: 4722-4729.
26. Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359: 492-507.
27. Yao XH, Ping YF, Chen JH, Chen DL, Xu CP, Zheng J, Wang JM, Bian XW (2008a) Production of angiogenic factors by human glioblastoma cells following activation of the G-protein coupled formylpeptide receptor FPR. J Neurooncol 86: 47-53.
28. Yao XH, Ping YF, Chen JH, Xu CP, Chen DL, Zhang R, Wang JM, Bian XW (2008b) Glioblastoma stem cells produce vascular endothelial growth factor by activation of a G-protein coupled formylpeptide receptor FPR. J Pathol 215: 369-376.
29. Zhou Y, Bian X, Le Y, Gong W, Hu J, Zhang X, Wang L, Iribarren P, Salcedo R, Howard OM, Farrar W, Wang JM (2005) Formylpeptide receptor FPR and the rapid growth of malignant human gliomas. J Natl Cancer Inst 97: 823-835.
30. Zlotnik A (2006) Chemokines and cancer. Int J Cancer 119: 2026-2029.